Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Final CTU new 2019 masthead1

September 1st, 2019

View Archives Issues

  • No Substantial Difference in Risk of Acquiring HIV in IUD, Implant, Injection Users

    Results from a large, randomized trial among African women found no substantial difference in HIV risk using the copper intrauterine device, the levonorgestrel implant, and the depot medroxyprogesterone acetate injection. The data counter research that suggested a potential association between some types of contraceptives and risk of acquiring HIV.

  • ACIP Recommends HPV Vaccination for Older Men and Women

    The Advisory Committee on Immunization Practices recently approved use of the 9-valent HPV vaccine for persons ages 27-45 years. The recommendation to expand use of the vaccine comes as findings from a large meta-analysis indicate that the HPV vaccine has substantially reduced infections and precancerous lesions. Providers are encouraged to discuss the potential benefits of HPV vaccination with patients in the mid-age category, addressing the reduced efficacy compared to vaccination within the younger target age range, as well as the reduced risk of high-grade disease and cervical cancer.

  • Medicaid Reimbursement Change Increases Interbirth Intervals Among Teens

    After changing its Medicaid policy to provide reimbursement for immediate postpartum long-acting reversible contraception (LARCs) separate from the global labor and delivery payment, South Carolina saw an increase in immediate postpartum LARC initiation and increased birth spacing among young women.

  • Research Continues Toward Potential Herpes Vaccine

    After promising research for a potential herpes vaccine stalled in 2018, scientists are finding new paths for investigation that may lead to a potential candidate. Recently published research by Yale University investigators may offer clues to an effective vaccine option.

  • Study Examines Effect of Vitamin D, Estradiol Deficiency on Metabolic Syndrome

    Menopause is associated with an increased risk for metabolic syndrome, a cluster of risk factors for cardiovascular disease and diabetes. New research indicates that vitamin D and estradiol may help protect against these conditions.

  • Focus on Integrative Approaches to Pain, Anxiety Management During Adolescent IUD Insertion

    On Jan. 1, 2018, The Joint Commission implemented new and revised pain assessment and management standards for accredited hospitals. The additions and revisions require hospitals to “provide at least one non-pharmacological pain treatment modality.” There are several non-pharmacologic approaches to offer adolescents to help manage anxiety and pain related to intrauterine device (IUD) insertions. Such methods include hypnotic language, music, heat therapy, social support (“IUD doula”), acupressure, and aromatherapy.

  • HIV Screening, PrEP Receive USPSTF Recommendation

    The U.S. Preventive Services Task Force (USPSTF) has issued final recommendations that providers screen for HIV in everyone ages 15-65 years, and all pregnant women as well as younger adolescents and older adults at increased risk for HIV. Pre-exposure prophylaxis (PrEP) also should be offered to people at high risk of HIV, USPSTF recommends. Since 2006, the CDC has recommended universal HIV screening at least once for people ages 13-64 years, with annual or more frequent rescreenings for persons at increased risk. However, new data indicate that such recommendations have not been fully implemented.

  • New Target May Lead to Chlamydia Treatment Options

    Reproductive health providers battle against chlamydia every day, as it is the most commonly reported sexually transmitted infection in the U.S. According to data from the CDC, more than 1.7 million cases were diagnosed in 2017, with 45% among females ages 15-24 years. New research has identified a potential target for drug treatment that may help develop alternate approaches to stem infections.